Enzalutamide significantly reduces morbidities associated with bone metastases in men with metastatic castration-resistant prostate cancer

Enzalutamide (XTANDI™) reduces the risk of skeletal-related events compared with placebo, as well as reducing pain and increasing quality of life in men with metastatic castration-resistant...